Montgomery College, Maryland’s largest and most diverse community college, provides the BioHealth Capital Region with dozens of qualified research and manufacturing associates each year.
Matan Companies chose the right time to enter the life sciences manufacturing sector of real estate. The Frederick-based real estate developer is well on its way to delivering the 2 million square feet of manufacturing space it promised through Progress Labs, a project dedicated exclusively to spec properties for life sciences manufacturing.
The Storied 25 Year History Behind the Baltimore Biotech Manufacturing Facility Producing COVID-19 Vaccines
Emergent Biosolutions’ vaccine manufacturing plant in Baltimore has been the subject of many headlines this past year for its’ role in producing several COVID-19 Vaccines. However, the history of this facility goes back more than two decades.
With the opening of its state-of-the-art facility in Rockville in 2017, GSK has been strengthening its manufacturing presence in the US. As a result, the site’s portfolio of programs and bulk production has been growing steadily, with
The BioHealth Capital Region (BHCR) has been witnessing a strong upward growth trajectory in recent years. The COVID-19 pandemic has only heightened the need for increased research, diagnostic and domestic manufacturing needs in the region. But while workforce needs are in demand, the right skills are in short supply.
GSK is hiring for a large number of full-time jobs to support an expanding portfolio of programs and the growth of their bulk production of several critical drugs manufactured at the site.
A few weeks ago, we wrote about how the BioHealth Capital Region’s (BHCR) biotech sector is booming. Advanced biomanufacturing, cell and gene therapy, vaccine development, and the medtech industries have all seen record growth over the past few years.
AstraZeneca is reportedly in talks to shift production of its coronavirus vaccine to a Maryland-based factory operated by Catalent, Inc.
Clene Announces Plan to Expand its Manufacturing Capacity of CNM-Au8, Closing of Up to $30 Million Debt Facility, and Financing Agreements for $9.25 Million At-the-Market Private Placement
Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using bioenergetic nanocatalysis, today announced that it is currently in negotiations to lease a 75,000 square foot facility in Elkton, Maryland, a few miles north of its current manufacturing site. Subject to the successful consummation of those negotiations, the site will be redeveloped to support Clene’s unique manufacturing needs; this redevelopment will enable the Company to materially increase its manufacturing capacity preparatory to the expected data release in H1 2022 from its Phase 3 registration trial evaluating CNM-Au8 as a treatment for amyotrophic lateral sclerosis (ALS).
Dr. Vipin Garg, Altimmune’s (ALT) CEO since 2018 and a biotech industry veteran, has successfully led the publicly-traded company through these turbulent pandemic waters. We recently caught up with Dr. Garg to discuss the pandemic, Altimmune’s deep product pipeline, his unique perspectives on the BioHealth Capital Region (BHCR), and the state of the U.S. supply chain and biotech manufacturing ecosystem.